US2022220205A1PendingUtilityA1

Dosing regimen of avelumab for the treatment of cancer

52
Assignee: PFIZERPriority: Oct 6, 2016Filed: Feb 9, 2022Published: Jul 14, 2022
Est. expiryOct 6, 2036(~10.2 yrs left)· nominal 20-yr term from priority
Inventors:Glen Ian AndrewsCarlo Leonel BelloSatjit Singh BrarShaonan WangPascal Girard
C07K 16/2827C07K 2317/24A61K 2039/505C07K 2317/14A61P 35/00A61K 2039/545
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.

Claims

exact text as granted — not AI-modified
1 - 45 . (canceled) 
     
     
         46 . A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 1200-2400 mg flat dose Q3W. 
     
     
         47 . The method of  claim 46 , wherein the dosing regimen is 1200 mg flat dose Q3W. 
     
     
         48 . The method of  claim 46 , wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer. 
     
     
         49 . The method of  claim 48 , wherein the cancer is NSCLC. 
     
     
         50 . The method of  claim 48 , wherein the cancer is MCC. 
     
     
         51 - 69 . (canceled) 
     
     
         70 . The method of  claim 47 , wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer. 
     
     
         71 . The method of  claim 70 , wherein the cancer is NSCLC. 
     
     
         72 . The method of  claim 70 , wherein the cancer is MCC.

Join the waitlist — get patent alerts

Track US2022220205A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.